ホーム › 多発性骨髄腫 › ウィスコンシン › Madison
Madison、WIにおける多発性骨髄腫の臨床試験
Madisonとその周辺地域（約30マイル以内）の拠点で、多発性骨髄腫に関する9件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
被験者募集中第3相
- Research Site, Madison
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
被験者募集中第1/2相
- University of Wisconsin Carbone Cancer Center, Madison
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
被験者募集中第2相
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma
被験者募集中第1/2相
- University of Wisconsin, Madison
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
被験者募集中第3相
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center-University Hospital, Madison
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
被験者募集中第3相
- William S Middleton VA Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
被験者募集中第2相
- University of Wisconsin - Carbone Cancer Center, Madison
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
被験者募集中第3相
- University of Wisconsin Hospital and Clinics, Madison
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
被験者募集中第2相
- University of Wisconsin Clinical Science Center, Madison
他の都市における多発性骨髄腫の試験
- New York City, NY60件の研究
- Boston, MA42件の研究
- Atlanta, GA41件の研究
- Houston, TX38件の研究
- Durham, NC37件の研究
- Nashville, TN32件の研究
- Denver, CO27件の研究
- Rochester, MN24件の研究
- St. Louis, MO24件の研究
- Columbus, OH24件の研究
- Baldwin Park, CA23件の研究
- Chicago, IL22件の研究
Madisonにおける他の研究
- 前立腺がん29件の研究
- 大腸癌22件の研究
- 乳がん22件の研究
- 転移性癌21件の研究
- 非小細胞肺癌16件の研究
- 急性骨髄性白血病16件の研究
- 悪性黒色腫15件の研究
- がん（全種類）14件の研究
- 卵巣がん13件の研究
- 胃癌11件の研究
- 肺がん10件の研究
- 膵臓がん10件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。